{ "FullStudy":{ "Rank":217609, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01519167", "OrgStudyIdInfo":{ "OrgStudyId":"DEX-10-16" }, "Organization":{ "OrgFullName":"Hospira, now a wholly owned subsidiary of Pfizer", "OrgClass":"INDUSTRY" }, "BriefTitle":"Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation", "OfficialTitle":"Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation" }, "StatusModule":{ "StatusVerifiedDate":"August 2015", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"October 2012" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"January 2014", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"January 2014", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 24, 2012", "StudyFirstSubmitQCDate":"January 24, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 26, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"May 5, 2015", "ResultsFirstSubmitQCDate":"August 7, 2015", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"August 14, 2015", "ResultsFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"March 16, 2017", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"March 20, 2017", "LastUpdatePostDateType":"Actual" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Hospira, now a wholly owned subsidiary of Pfizer", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.", "DetailedDescription":"This study was designed to evaluate the safety of a continuous infusion of dexmedetomidine (1 mcg/kg loading dose with 0.6 mcg/kg/hr initial maintenance dose and titrated between 0.2-1.0 mcg/kg/hr) administered to subjects requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures that are expected to take more than 30 minutes." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Ultrasound", "CT Scans", "MRIs" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 4" ] }, "DesignInfo":{ "DesignInterventionModel":"Single Group Assignment", "DesignPrimaryPurpose":"Treatment", "DesignMaskingInfo":{ "DesignMasking":"None (Open Label)" } }, "EnrollmentInfo":{ "EnrollmentCount":"91", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"Dexmedetomidine", "ArmGroupType":"Experimental", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: Dexmedetomidine", "Drug: Midazolam", "Drug: Fentanyl" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"Dexmedetomidine", "InterventionDescription":"0.1 - 1.0 mcg/kg/hr IV", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Dexmedetomidine" ] } },{ "InterventionType":"Drug", "InterventionName":"Midazolam", "InterventionDescription":"0.025 - 2 mg/kg IV", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Dexmedetomidine" ] } },{ "InterventionType":"Drug", "InterventionName":"Fentanyl", "InterventionDescription":"0.5 - 3 mcg/kg IV", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "Dexmedetomidine" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Number of Subjects Who Had Success in Sedation", "PrimaryOutcomeDescription":"Success in sedation was defined by a combined endpoint which was the combination of the following:\n\nSubject had adequate level of sedation (University of Michigan Sedation Scale [UMSS] score between 1 to 3 [minimally sedated to deeply sedated] or Neonatal Pain, Agitation and Sedation Scale [N-PASS] score between -5 to -2 [Light sedation]) at least 80% of the time the subject was given the study drug.\nSubject had successfully completed the procedure without a need for rescue sedation (Midazolam).\nSubject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status", "PrimaryOutcomeTimeFrame":"From baseline to end of post-treatment period (approximately 24 hours)" } ] }, "SecondaryOutcomeList":{ "SecondaryOutcome":[ { "SecondaryOutcomeMeasure":"Number of Subjects Not Receiving Rescue Midazolam", "SecondaryOutcomeDescription":"Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Number of Subjects Who Were Adequately Sedated at Least 80% of Time", "SecondaryOutcomeDescription":"Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion", "SecondaryOutcomeDescription":"Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Frequency of Midazolam Required for Sedation", "SecondaryOutcomeDescription":"Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Frequency of Fentanyl Use for Analgesia", "SecondaryOutcomeDescription":"Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Total Amount of Rescue Sedation (Midazolam)", "SecondaryOutcomeDescription":"Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Total Amount of Rescue Analgesia (Fentanyl)", "SecondaryOutcomeDescription":"Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" },{ "SecondaryOutcomeMeasure":"Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication", "SecondaryOutcomeTimeFrame":"During the treatment period, up to approximately 24 hours" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nSubject is ≥28 weeks gestational age and <17 years of age.\n\n- Preterm subjects ≥28 weeks through <38 weeks, gestational age; (Note: Gestational age will be calculated as the time elapsed between the first day of the last menstrual period to the day of enrollment. If pregnancy was achieved using assisted reproductive technology, gestational age will be calculated by adding 2 weeks to the gestational age as calculated above.)\n\nSubject is American Society of Anesthesiologists (ASA) Physical Status I, II or III.\nSubject requires non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) in an operating or procedure room with an an intensivist, anesthesiologist or dental anesthesiologist in attendance.\n\nScheduled for an elective procedure that falls into one of the following three populations:\n\nNon-invasive diagnostic/therapeutic procedures (NIDTP): including ultrasound (US), computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, transthoracic echocardiogram (TTE);\nMinimally invasive diagnostic/therapeutic procedures (MIDTP): including minimally invasive procedures performed under US or CT guidance (e.g. US or CT-guided solid organ biopsy), and routine myocardial biopsies in cardiac transplant recipients;\nSurgical procedures: including small surgical procedures (e.g. excisions, biopsies) and dental procedures (e.g. extractions, pulpectomy, pediatric rehabilitation dental procedures, filings and crowns).\nDuration of the procedure is expected to take at least 30 minutes to complete.\n\nIf female, subject is non-lactating and is either:\n\nNot of childbearing potential, defined as pre-menarche, or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.\nOf childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of birth control: oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.\nSubject's parent(s) or legally acceptable representative(s) has/have voluntarily signed and dated the informed consent document approved by the Institutional Review Board. Assent will be obtained where age-appropriate and according to state regulations.\n\nExclusion Criteria:\n\nSubjects weight at the time of screening is less than 1000 g.\nSubject has received general anesthesia within 7 days prior to study drug administration.\nSubject has participated in an experimental/investigational drug study within 30 days prior to study drug administration.\nSubject has been exposed to dexmedetomidine within 48 hours prior to study drug administration.\nSubject that has been previously enrolled in this study (DEX-10-16).\nSubject requires endotracheal intubation or laryngeal mask airway (LMA).\nSubject is with neurological conditions that in the opinion of the Investigator will preclude reliable assessment of sedation scoring. Examples include, but are not limited to the following: cerebral palsy, autism, severe mental retardation, etc.\nSubject has central nervous system (CNS) disease with an anticipated potential for increased intracranial pressure, an uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment.\nSubject requires epidural or spinal anesthesia.\nSubject has received treatment with an alpha-2 agonist or antagonist within 14 days prior to study drug administration.\nSubject has a known allergy to dexmedetomidine, midazolam or fentanyl.\nSubject is requiring cardiac catheterization for the purpose of conducting an electrophysiology (EP) evaluation or percutaneous intervention (i.e. angioplasty).\nSubject for whom opiates, benzodiazepines, dexmedetomidine or other alpha-2 agonists are contraindicated.\nSubject has received an IV opioid within one hour, or oral/intramuscular (PO/IM) opioid within four hours, prior to the start of study drug administration.\nSubject has received any pre-induction medication (ie, ketamine, chloral hydrate, benzodiazepines) within 4 hours prior to the start of study drug administration.\nSubject has acute myocardial infarction recently diagnosed by confirmatory laboratory findings within 6 weeks of screening.\nSubject has moderate to severe sleep apnea syndrome.\nSubject has oxygen saturation (SpO2) ≤90% at screening or baseline, except for patients with known cyanotic heart disease undergoing cardiac catheterization.\n\nSubject has bradycardia immediately before dosing, according to respective age group.\n\n≥28 weeks to <1 month: Heart Rate (HR) <120 beats per minute (bpm)\n1 month to <3 months: HR <100 bpm\n3 months to <6 months: HR <90 bpm\n6 months to <1 year: HR <80 bpm\n1 year to <2 years: HR <70 bpm\n2 years to <6 years: HR <60 bpm\n6 years to <12 years: HR <55 bpm\n12 years to 17 years: HR <50 bpm;\n\nNote: Subject can be reassessed after 5 minutes\n\nSubject has hypotension immediately before dosing, according to respective age group.\n\n≥28 weeks to <1 month: <60 mmHg (systolic blood pressure [SBP])\n1 month to <12 months: <70 mmHg (SBP)\n1 year to <10 years: <70 + (2 X age in years) mmHg (SBP)\n10 years to 17 years: <90 mmHg (SBP);\n\nNote: Subject can be reassessed after 5 minutes\n\nSubject has a presence of second-degree or third-degree heart block at screening or baseline. The presence of a temporary or permanent pacemaker will waive this exclusion criterion.\nSubject has acute febrile illness, with a temperature (core or tympanic) ≥38.0°C.\nSubject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.", "HealthyVolunteers":"No", "Gender":"All", "MinimumAge":"28 Weeks", "MaximumAge":"16 Years", "StdAgeList":{ "StdAge":[ "Child" ] } }, "ContactsLocationsModule":{ "LocationList":{ "Location":[ { "LocationCity":"Little Rock", "LocationState":"Arkansas", "LocationZip":"72202", "LocationCountry":"United States" },{ "LocationCity":"Anaheim", "LocationState":"California", "LocationZip":"92801", "LocationCountry":"United States" },{ "LocationCity":"Stanford", "LocationState":"California", "LocationZip":"94305", "LocationCountry":"United States" },{ "LocationCity":"Miami", "LocationState":"Florida", "LocationZip":"33136", "LocationCountry":"United States" },{ "LocationCity":"Durham", "LocationState":"North Carolina", "LocationZip":"27710", "LocationCountry":"United States" },{ "LocationCity":"Pittsburgh", "LocationState":"Pennsylvania", "LocationZip":"15224", "LocationCountry":"United States" },{ "LocationCity":"Nashville", "LocationState":"Tennessee", "LocationZip":"37232-9070", "LocationCountry":"United States" },{ "LocationCity":"Dallas", "LocationState":"Texas", "LocationZip":"75235", "LocationCountry":"United States" },{ "LocationCity":"Sandy", "LocationState":"Utah", "LocationZip":"84096", "LocationCountry":"United States" },{ "LocationCity":"San Juan", "LocationZip":"00936-5067", "LocationCountry":"Puerto Rico" },{ "LocationCity":"San Juan", "LocationZip":"00936", "LocationCountry":"Puerto Rico" } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowPreAssignmentDetails":"The number of subjects enrolled was 91, of that 90 subjects received study drug. The remaining 1 subject not treated due to subject being a screen failure.", "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"Dose Level 1", "FlowGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "FlowGroupId":"FG001", "FlowGroupTitle":"Dose Level 2", "FlowGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Overall Study", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"89" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"1" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"81" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"0" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"8" } ] } } ] }, "FlowDropWithdrawList":{ "FlowDropWithdraw":[ { "FlowDropWithdrawType":"Diagnostic/TherapeuticProcedureCompleted", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"3" } ] } },{ "FlowDropWithdrawType":"Adverse Event", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"1" } ] } },{ "FlowDropWithdrawType":"Lack of Efficacy", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"1" } ] } },{ "FlowDropWithdrawType":"Medical condition changes&deep sedation", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"2" } ] } },{ "FlowDropWithdrawType":"Physician Decision", "FlowReasonList":{ "FlowReason":[ { "FlowReasonGroupId":"FG000", "FlowReasonNumSubjects":"0" },{ "FlowReasonGroupId":"FG001", "FlowReasonNumSubjects":"1" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselinePopulationDescription":"Safety Evaluable Population: All subjects who receive any amount of study drug. All safety analyses will be performed on this population.", "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"Dose Level 1", "BaselineGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "BaselineGroupId":"BG001", "BaselineGroupTitle":"Dose Level 2", "BaselineGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" },{ "BaselineGroupId":"BG002", "BaselineGroupTitle":"Total", "BaselineGroupDescription":"Total of all reporting groups" } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"1" },{ "BaselineDenomCountGroupId":"BG001", "BaselineDenomCountValue":"89" },{ "BaselineDenomCountGroupId":"BG002", "BaselineDenomCountValue":"90" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Full Range", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0.1", "BaselineMeasurementLowerLimit":"0.1", "BaselineMeasurementUpperLimit":"0.1" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"7.97", "BaselineMeasurementLowerLimit":"0.3", "BaselineMeasurementUpperLimit":"17.3" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"7.89", "BaselineMeasurementLowerLimit":"0.1", "BaselineMeasurementUpperLimit":"17.3" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"41" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"41" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"1" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"48" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"49" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Ethnicity (NIH/OMB)", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Hispanic or Latino", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"23" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"23" } ] } },{ "BaselineCategoryTitle":"Not Hispanic or Latino", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"1" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"66" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"67" } ] } },{ "BaselineCategoryTitle":"Unknown or Not Reported", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Race (NIH/OMB)", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"American Indian or Alaska Native", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } },{ "BaselineCategoryTitle":"Asian", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"1" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"1" } ] } },{ "BaselineCategoryTitle":"Native Hawaiian or Other Pacific Islander", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } },{ "BaselineCategoryTitle":"Black or African American", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"1" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"22" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"23" } ] } },{ "BaselineCategoryTitle":"White", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"60" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"60" } ] } },{ "BaselineCategoryTitle":"More than one race", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } },{ "BaselineCategoryTitle":"Unknown or Not Reported", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"6" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"6" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Number of Subjects Who Had Success in Sedation", "OutcomeMeasureDescription":"Success in sedation was defined by a combined endpoint which was the combination of the following:\n\nSubject had adequate level of sedation (University of Michigan Sedation Scale [UMSS] score between 1 to 3 [minimally sedated to deeply sedated] or Neonatal Pain, Agitation and Sedation Scale [N-PASS] score between -5 to -2 [Light sedation]) at least 80% of the time the subject was given the study drug.\nSubject had successfully completed the procedure without a need for rescue sedation (Midazolam).\nSubject had undergone the procedure without artificial ventilation or intervention to restore baseline or normal hemodynamic status", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"participants", "OutcomeMeasureTimeFrame":"From baseline to end of post-treatment period (approximately 24 hours)", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number of Subjects Not Receiving Rescue Midazolam", "OutcomeMeasureDescription":"Number of subjects who did not receive any rescue midazolam for sedation during the study drug infusion.", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"participants", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"12" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"5" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number of Subjects Who Have Undergone Procedures Without Artificial Ventilation or Intervention", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"participants", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"1" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"37" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"19" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"12" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number of Subjects Who Were Adequately Sedated at Least 80% of Time", "OutcomeMeasureDescription":"Subjects who are adequately sedated (UMSS score of 1 to 3 or NPASS score of -5 to -2) at least 80% of the time sedated with the study drug", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"participants", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"21" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"7" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Time to First Dose of Rescue Midazolam From Start of Dexmedetomidine Infusion", "OutcomeMeasureDescription":"Kaplan-Meier estimates of time in minutes to first dose of rescue midazolam from onset of study drug infusion", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"95% Confidence Interval", "OutcomeMeasureUnitOfMeasure":"Hours", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"NA", "OutcomeMeasurementComment":"There was one subject in this group (n=1) and the subject did not receive rescue midazolam." },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"23.5", "OutcomeMeasurementLowerLimit":"16.00", "OutcomeMeasurementUpperLimit":"28.00" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"NA", "OutcomeMeasurementComment":"No subjects were in the MIDTP group" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.00", "OutcomeMeasurementLowerLimit":"17.00", "OutcomeMeasurementUpperLimit":"34.00" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"NA", "OutcomeMeasurementComment":"No subjects were in the surgical procedures group" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"20.00", "OutcomeMeasurementLowerLimit":"15.00", "OutcomeMeasurementUpperLimit":"25.00" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Frequency of Midazolam Required for Sedation", "OutcomeMeasureDescription":"Frequency of rescue sedation (midazolam) required to maintain a subject within the target sedation range (UMSS score greater than 1 or N-PASS score less than -2).", "OutcomeMeasurePopulationDescription":"Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"Full Range", "OutcomeMeasureUnitOfMeasure":"Occurrence", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"0" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"59" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=0, 28)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"4" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 20)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"2" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"2" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Frequency of Fentanyl Use for Analgesia", "OutcomeMeasureDescription":"Frequency of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure.", "OutcomeMeasurePopulationDescription":"Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Median", "OutcomeMeasureDispersionType":"Full Range", "OutcomeMeasureUnitOfMeasure":"Occurrence", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"0" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"40" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=0, 6)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"3" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 22)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"5" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.50", "OutcomeMeasurementLowerLimit":"1", "OutcomeMeasurementUpperLimit":"5" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Total Amount of Rescue Sedation (Midazolam)", "OutcomeMeasureDescription":"Total amount of rescue sedation (midazolam) required from the start of IV sedation to completion of the procedure", "OutcomeMeasurePopulationDescription":"Number of subjects who received any amount (mg) of rescue midazolam for sedation in efficacy evaluable population.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"milligram", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"0" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"59" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=0, 28)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.62", "OutcomeMeasurementSpread":"1.611" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 20)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"1.70", "OutcomeMeasurementSpread":"0.767" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 11)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2.45", "OutcomeMeasurementSpread":"0.907" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Total Amount of Rescue Analgesia (Fentanyl)", "OutcomeMeasureDescription":"Total amount of rescue analgesia (fentanyl) required from the start of IV sedation to completion of the procedure", "OutcomeMeasurePopulationDescription":"Number of subjects who received any amount (mg) of rescue fentanyl for analgesia in efficacy evaluable population.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"microgram", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"0" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"40" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=0, 6)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"10.83", "OutcomeMeasurementSpread":"8.010" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 22)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"61.86", "OutcomeMeasurementSpread":"65.740" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"104.83", "OutcomeMeasurementSpread":"72.007" } ] } } ] } } ] } },{ "OutcomeMeasureType":"Secondary", "OutcomeMeasureTitle":"Number of Subjects Converted to Alternative Sedation or Anesthetic Therapy Due to Failure of Treatment of Study Drug and Rescue Medication", "OutcomeMeasurePopulationDescription":"Efficacy Evaluable Population (Participants who received study drug infusion for at least 30 minutes and had no major protocol deviations)", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Number", "OutcomeMeasureUnitOfMeasure":"Participants", "OutcomeMeasureTimeFrame":"During the treatment period, up to approximately 24 hours", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Dose Level 1", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Dose Level 2", "OutcomeGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"1" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"77" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeClassTitle":"NIDTP (n=1, 40)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"MIDTP (n=0, 25)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"0" } ] } } ] } },{ "OutcomeClassTitle":"Surgical procedures (n=0, 12)", "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"0" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"2" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"1", "EventsTimeFrame":"Non-serious adverse events from start of study drug administration until 24(±12) hours following study drug discontinuation. Reported serious adverse events from the time the subject signed informed consent until 30 days after study drug discontinuation.", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"Dose Level 1", "EventGroupDescription":"Dexmedetomidine Loading dose 0.1 mcg/kg and Maintenance dose 0.1 mcg/kg/hr", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"1", "EventGroupOtherNumAffected":"1", "EventGroupOtherNumAtRisk":"1" },{ "EventGroupId":"EG001", "EventGroupTitle":"Dose Level 2", "EventGroupDescription":"Dexmedetomidine Loading dose 1 mcg/kg and Maintenance dose 0.6 mcg/kg/hr", "EventGroupSeriousNumAffected":"1", "EventGroupSeriousNumAtRisk":"89", "EventGroupOtherNumAffected":"66", "EventGroupOtherNumAtRisk":"89" } ] }, "SeriousEventList":{ "SeriousEvent":[ { "SeriousEventTerm":"Syncope", "SeriousEventOrganSystem":"Nervous system disorders", "SeriousEventSourceVocabulary":"MedDRA (14.1)", "SeriousEventAssessmentType":"Systematic Assessment", "SeriousEventStatsList":{ "SeriousEventStats":[ { "SeriousEventStatsGroupId":"EG000", "SeriousEventStatsNumEvents":"0", "SeriousEventStatsNumAffected":"0", "SeriousEventStatsNumAtRisk":"1" },{ "SeriousEventStatsGroupId":"EG001", "SeriousEventStatsNumEvents":"1", "SeriousEventStatsNumAffected":"1", "SeriousEventStatsNumAtRisk":"89" } ] } } ] }, "OtherEventList":{ "OtherEvent":[ { "OtherEventTerm":"Bradycardia", "OtherEventOrganSystem":"Cardiac disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"4", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Tachycardia", "OtherEventOrganSystem":"Cardiac disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Diarrhoea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Nausea", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Vomiting", "OtherEventOrganSystem":"Gastrointestinal disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Blood pressure diastolic decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Blood pressure systolic decreased", "OtherEventOrganSystem":"Investigations", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Hyperglycaemia", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Hyperkalaemia", "OtherEventOrganSystem":"Metabolism and nutrition disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Headache", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"3", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Somnolence", "OtherEventOrganSystem":"Nervous system disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Agitation", "OtherEventOrganSystem":"Psychiatric disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Hypoxia", "OtherEventOrganSystem":"Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Respiratory depression", "OtherEventOrganSystem":"Respiratory, thoracic and mediastinal disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"53", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Rash", "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"1", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Hypertension", "OtherEventOrganSystem":"Vascular disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"2", "OtherEventStatsNumAtRisk":"89" } ] } },{ "OtherEventTerm":"Hypotension", "OtherEventOrganSystem":"Vascular disorders", "OtherEventSourceVocabulary":"MedDRA (14.1)", "OtherEventAssessmentType":"Systematic Assessment", "OtherEventStatsList":{ "OtherEventStats":[ { "OtherEventStatsGroupId":"EG000", "OtherEventStatsNumAffected":"0", "OtherEventStatsNumAtRisk":"1" },{ "OtherEventStatsGroupId":"EG001", "OtherEventStatsNumAffected":"37", "OtherEventStatsNumAtRisk":"89" } ] } } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictionType":"OTHER", "AgreementRestrictiveAgreement":"Yes", "AgreementOtherDetails":"The Investigator may not submit the results of the study for publication without the prior written consent of Hospira." }, "PointOfContact":{ "PointOfContactTitle":"Marcelo Garcia de Rocha MD, Global Medical Director", "PointOfContactOrganization":"Hospira", "PointOfContactEMail":"marcelo.rocha@hospira.com", "PointOfContactPhone":"224-212-4424" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000005283", "InterventionMeshTerm":"Fentanyl" },{ "InterventionMeshId":"D000008874", "InterventionMeshTerm":"Midazolam" },{ "InterventionMeshId":"D000020927", "InterventionMeshTerm":"Dexmedetomidine" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000006993", "InterventionAncestorTerm":"Hypnotics and Sedatives" },{ "InterventionAncestorId":"D000002492", "InterventionAncestorTerm":"Central Nervous System Depressants" },{ "InterventionAncestorId":"D000045505", "InterventionAncestorTerm":"Physiological Effects of Drugs" },{ "InterventionAncestorId":"D000018712", "InterventionAncestorTerm":"Analgesics, Non-Narcotic" },{ "InterventionAncestorId":"D000000700", "InterventionAncestorTerm":"Analgesics" },{ "InterventionAncestorId":"D000018689", "InterventionAncestorTerm":"Sensory System Agents" },{ "InterventionAncestorId":"D000018373", "InterventionAncestorTerm":"Peripheral Nervous System Agents" },{ "InterventionAncestorId":"D000058647", "InterventionAncestorTerm":"Adrenergic alpha-2 Receptor Agonists" },{ "InterventionAncestorId":"D000000316", "InterventionAncestorTerm":"Adrenergic alpha-Agonists" },{ "InterventionAncestorId":"D000000322", "InterventionAncestorTerm":"Adrenergic Agonists" },{ "InterventionAncestorId":"D000018663", "InterventionAncestorTerm":"Adrenergic Agents" },{ "InterventionAncestorId":"D000018377", "InterventionAncestorTerm":"Neurotransmitter Agents" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" },{ "InterventionAncestorId":"D000000701", "InterventionAncestorTerm":"Analgesics, Opioid" },{ "InterventionAncestorId":"D000009294", "InterventionAncestorTerm":"Narcotics" },{ "InterventionAncestorId":"D000000759", "InterventionAncestorTerm":"Adjuvants, Anesthesia" },{ "InterventionAncestorId":"D000018686", "InterventionAncestorTerm":"Anesthetics, Intravenous" },{ "InterventionAncestorId":"D000018681", "InterventionAncestorTerm":"Anesthetics, General" },{ "InterventionAncestorId":"D000000777", "InterventionAncestorTerm":"Anesthetics" },{ "InterventionAncestorId":"D000014151", "InterventionAncestorTerm":"Anti-Anxiety Agents" },{ "InterventionAncestorId":"D000014149", "InterventionAncestorTerm":"Tranquilizing Agents" },{ "InterventionAncestorId":"D000011619", "InterventionAncestorTerm":"Psychotropic Drugs" },{ "InterventionAncestorId":"D000018757", "InterventionAncestorTerm":"GABA Modulators" },{ "InterventionAncestorId":"D000018682", "InterventionAncestorTerm":"GABA Agents" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M10428", "InterventionBrowseLeafName":"Midazolam", "InterventionBrowseLeafAsFound":"Midazolam", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M21246", "InterventionBrowseLeafName":"Dexmedetomidine", "InterventionBrowseLeafAsFound":"Dexmedetomidine", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M7001", "InterventionBrowseLeafName":"Fentanyl", "InterventionBrowseLeafAsFound":"Fentanyl", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M8626", "InterventionBrowseLeafName":"Hypnotics and Sedatives", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2613", "InterventionBrowseLeafName":"Analgesics", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19370", "InterventionBrowseLeafName":"Analgesics, Non-Narcotic", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19330", "InterventionBrowseLeafName":"Adrenergic Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2249", "InterventionBrowseLeafName":"Adrenergic alpha-Agonists", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2254", "InterventionBrowseLeafName":"Adrenergic Agonists", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19088", "InterventionBrowseLeafName":"Neurotransmitter Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2614", "InterventionBrowseLeafName":"Analgesics, Opioid", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M10828", "InterventionBrowseLeafName":"Narcotics", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2688", "InterventionBrowseLeafName":"Anesthetics", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19350", "InterventionBrowseLeafName":"Anesthetics, Intravenous", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19345", "InterventionBrowseLeafName":"Anesthetics, General", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M15488", "InterventionBrowseLeafName":"Anti-Anxiety Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M13057", "InterventionBrowseLeafName":"Psychotropic Drugs", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M19411", "InterventionBrowseLeafName":"GABA Modulators", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"AdjAn", "InterventionBrowseBranchName":"Adjuvants, Anesthesia" },{ "InterventionBrowseBranchAbbrev":"CNSDep", "InterventionBrowseBranchName":"Central Nervous System Depressants" },{ "InterventionBrowseBranchAbbrev":"PsychDr", "InterventionBrowseBranchName":"Psychotropic Drugs" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" },{ "InterventionBrowseBranchAbbrev":"Analg", "InterventionBrowseBranchName":"Analgesics" } ] } } } } } }